2Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma[J]. Ann Hematol, 2000,79:544.
3Laroche M, Brousset P, Ludot I, et al. Increased vascularization in myeloma[J]. Eur J Hematol, 2001,66 (1):89.
4Vacca A, Ribatti D, Presta M ,et al. Bone marrow neovascularization,plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma[J]. Blood, 1999,93 (9) : 3064.
5Salven P. Angiogenesis in lymphoproliferative disorders[J]. Acta Haematol,2001,106(4): 184.
6Aguayo A, Kantarjian H, Manshouri T, et al. Anglogenesis in acute and chronic leukemia and myelodysplastic syndrome[J]. Blood, 2000,96 (6) : 2240.
7Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia[J]. Blood, 2000,95 (8) : 2637.
8Perez -Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia[J]. Am J Pathol,1997,150(5) : 815.
9Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia[J]. Blood, 1997, 89(6) : 1870.
10Salven P, Teerenhovi L, Joensun H, et al. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma[J]. Blood, 1997,90(8): 3167.
二级参考文献13
1Laroche M, Brousset P, Ludot I, et al. Increased vascularization in myeloma. Eur J Haematol, 2001,66:89-93.
2Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res, 2000, 6:3111-3116.
3Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol, 2000,79:574-577.
4Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol, 2000, 109:89-96.
5Dimopoulos MA, Zervas K,Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol, 2001,12:991-995.
6Nehls V, Drenckhahn D. A microcarrier-based cocultivation system for the investigation of factors and cells involved in angiogenesis in three-dimensional fibrin matrices in vitro. Histochem Cell Biol, 1995,104:459-466.
7Deckers MM, Karperien M, van der Bent C, et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology, 2000, 141:1667-1674.
8Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Huntingt), 2000, 14 (12 Suppl 13):11-16.
9Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999,341:1565-1571.
10Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost, 2001, 86:23-33.
